Zobrazeno 1 - 6
of 6
pro vyhledávání: '"929"'
Autor:
Oscar Arrieta, R. Bernabé, Judith Dalmau, Miguel Angel Molina-Vila, Jorge Carrillo, Remedios Blanco, Teresa Moran, Clara Mayo de las Casas, Jillian Wilhelmina Paulina Bracht, Bonaventura Clotet, Christian Brander, Jordi Argilaguet, Julia G. Prado, Mariano Provencio, Javier Garcia-Corbacho, Ana Giménez-Capitán, Mónica Garzón, Erika Aldeguer, Andrés F. Cardona, Rafael Rosell, Bartomeu Massuti, Javier de Castro, Maria Gonzalez-Cao, Javier Martinez-Picado, Andreas Meyerhans, Sonia Rodríguez, Oscar Juan, Ana Drozdowskyj, Chung-Ying Huang, J. Blanco
Publikováno v:
Cancer Research. 80:929-929
Introduction: Treatment with anti PD-1/PD-L1 antibodies has demonstrated clinical activity in different types of solid tumors, but only 20 to 30% of patients (pts) respond to these immune checkpoint inhibitors (ICIs). Therefore, predictive biomarkers
Autor:
Bradley M. Turner, Danielle E. Desa, Edward B. Brown, Brandon Buscaglia, Robert L. Strawderman, Robert L. Hill, David G. Hicks
Publikováno v:
Cancer Research. 79:P6-09
Background: Over-expression of Human Epidermal Growth Factor receptor-2 (HER2) in breast cancer is associated with an aggressive clinical course and poor prognosis. Targeting HER2 over-expression has been shown to be a remarkably effective therapeuti
Publikováno v:
Cancer Research. 79:P1-10
Background: Type II diabetes (T2D) has been found to modestly (10-20%) increase risk for breast cancer (BC) in mostly white populations. Some studies indicate that this association varies by BC receptor subtype, suggesting that T2D increases risk spe
Autor:
Romualdo Barroso-Sousa, Priti Kumari, Andrew D. Cherniack, Alice H. Berger, Deborah A. Dillon, Ethan Cerami, EP Winer, Ian E. Krop, Neal I. Lindeman, N Wagle, Ana C. Garrido-Castro, Melissa E. Hughes, Brittany L. Bychkovsky, S Di Lascio, H Guo, Nu Lin, Laura E. MacConaill, Janet Files, Elizabeth A. Mittendorf
Publikováno v:
Cancer Research. 79:PD9-01
Background: Discordance in hormone receptor (HR) status between primary (p) tumors and metastatic (m) recurrences has been widely described. Loss of estrogen and progesterone receptor expression occurs in ˜12% of asynchronous recurrences, leading to
Autor:
Anna E. Coghill, Andrea N. Burnett-Hartman, Michael N. Passarelli, Polly A. Newcomb, Karen W. Makar
Publikováno v:
Cancer Research. 72:1671-1671
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The prostaglandin synthesis pathway is critical for regulation of inflammatory processes in the colon and plays a well-defined role in colorectal carcinogenesis. Gene
Publikováno v:
Cancer Research. 69:4105
Abstract #4105 Introduction: The decision to treat women with hormone receptor-positive breast cancer with chemotherapy in addition to hormonal therapy is complex. Models have been developed to assist physicians in estimating survival benefit associa